IGF2BP1 and pancreatic neoplasm: Furthermore, pancreatic cancer patients with lower METTL3, METTL14, RBMX, FTO, ALKBH5, YTHDF1, and YTHDC1 mRNA expression levels or higher VIRMA, HNRNPA2B1, EIF3A, IGF2BP1, IGF2BP2, and IGF2BP3 mRNA expression levels had significantly poorer OS (P < 0.05, Fig. 6C, D).